Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia aortic valve, the first in a new class of resilient heart valves.

September 21, 2017 — Toshiba Medical will highlight its latest magnetic resonance imaging (MRI) technology, led by the ...

September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published ...

Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress, Sept. 16-20 in Copenhagen, Denmark.

The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, according to research and consulting firm GlobalData. This represents an impressive compound annual growth rate of 15.7 percent.

Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its technology in Europe.

Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating the efficacy of Philips Spectranetics' Stellarex .035-inch drug-coated balloon (DCB) for peripheral arterial disease (PAD) in comparison to uncoated balloon angioplasty. Marianne Brodmann, M.D., of the Medical University of Graz in Austria, presented the data as a late-breaking trial at the Vascular Interventional Advances (VIVA 17) Annual Conference, Sept. 11-14 in Las Vegas.